biotech
I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space
I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development
Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular
Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology
Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks
Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO
From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics
Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.
Belharra Biotech Cuts 21 Jobs Amid Industry-Wide Restructuring
Belharra Biotech, layoffs, chemoproteomics, biotech industry, restructuring
Dimension Secures $500M for Second Fund, Focusing on the Intersection of Science and Technology
Dimension, Venture Capital, Science, Technology, Biotech, AI, Machine Learning, Life Sciences, Innovation
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
Relay Therapeutics Partners with Elevar Therapeutics in $500M Deal for Lirafugratinib in Rare Cancer Treatment
Relay Therapeutics, Elevar Therapeutics, Lirafugratinib, FGFR2-Driven Cholangiocarcinoma, Rare Cancer Treatment, Biotech Partnership
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership